about
Assessment of the pharmacodynamic properties of antimalarial drugs in vivoSafety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous dosesActivities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosisCorrelation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein bindingAnimal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.Dihydrostreptomycin or streptomycin in combination with penicillin G in dairy cattle therapeutics: a review and re-analysis of published data. Part 1: clinical pharmacology.Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patientsPharmacodynamics of fluconazole in a murine model of systemic candidiasis.In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia modelPharmacokinetics of an ampicillin-sulbactam combination after intravenous and intramuscular administration to sheep.Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniaeEfficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniaeAltered pharmacokinetics of ceftazidime in critically ill patients.In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasisPharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis.Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion.In vivo verification of in vitro model of antibiotic treatment of device-related infection.Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program.Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection modelProtein binding and serum bactericidal activities of vancomycin and teicoplanin.Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsCerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies.Penetration of cefetamet pivoxil and cefuroxime axetil into the maxillary sinus mucosa at steady state.Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal modelDevelopment of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenemEfficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae.Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities.In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patientsPharmacokinetic study of cefodizime and ceftriaxone in sera and bones of patients undergoing hip arthroplastyVersatility of aminoglycosides and prospects for their future.Comparative study of the effects of four cephalosporins against Escherichia coli in vitro and in vivo.Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curvePulmonary disposition of antimicrobial agents: methodological considerations.
P2860
Q24670346-EED029D1-2553-4284-A920-43E770A0A868Q28251630-7235FBB4-EA83-40F8-B9CE-3A6F0A9BAC1CQ28344950-F2A44866-FF9D-49FA-99E6-42675CCF42FCQ28353204-C597F8E7-268C-470E-994E-9A0258EE8EC6Q30660609-D8E08314-E825-4A57-98AD-9F390B093B56Q30995411-A334B323-D343-4199-B841-966DB5EBA61DQ33541485-BBF6D898-586B-4C90-B45A-26B7DEF42254Q33694347-E70CABD4-34AE-4F43-B933-DAEB99C30F5FQ33695281-34778F8E-AB14-41A2-AFA8-6F41CF74FAF3Q33757851-63E6076C-D326-4F42-9198-52E01C30A330Q33923512-ADAA14FA-CA41-4B1C-8CB2-209747D71595Q33975832-33A5A93F-0BCD-47D3-9D50-55FB0A520999Q33975838-EE99E695-7FF1-407B-AAD3-9A2D4A1894A8Q33977268-71869118-5E90-4C61-8969-27A230B79A60Q33979438-0C9E1644-77E0-496E-829D-7412B7EEB2ADQ33980421-18FB37D0-5D15-44FF-B1A0-F425FE5EF595Q33981666-A63C5042-7A65-480C-932E-31DA773A6930Q33983119-0C3977B7-88B0-4C89-8895-1F1D2E808A17Q34139031-E312F648-B252-4DA0-A260-91358655F6B9Q34169255-E153849A-CD33-488B-A2A0-42D865F5E12AQ35013772-CF30EDF2-26D5-423C-830F-F1169FC517F1Q35114527-B3B9786D-9330-419C-B130-C4E042B05AE2Q35116767-4B8F13DF-09B1-4A0A-8D3B-34B71055453FQ35116889-63F0A725-E992-46D6-8D58-83E8468DA2B3Q35117243-3B89E99B-F27A-4831-A568-8DD573F070D4Q35117545-F4583AF1-E36E-41FC-96C5-3A22C5719687Q35123061-D5E907B7-206D-408A-944F-FDE1076553E7Q35123123-9A46859A-9A69-4C25-B60A-A3AD470BB1D6Q35123284-A3A83A81-C9BA-4138-92BC-DE513C14C057Q35123334-424BABA3-BFF4-44F3-B0D6-FF63DDB224CEQ35129635-41A2EEAE-F1AF-4FF6-AD1F-A5B3852DA36CQ35129690-DE4D737A-CE90-4708-88B8-C06B58C4EA12Q35130268-0EB2E262-D519-4188-A4B0-5F3999B45718Q35135686-48C7FFDB-EAC1-4E00-B2F8-9F3246BBC5C7Q35138316-3F787852-1B71-46DC-A386-63879CBE8E65Q35138664-C0BFC68F-ED7F-41AA-9D0C-741C76C3A276Q35176271-81C66B26-0FC5-4DDB-94BD-47576F604C6AQ35277051-D65B2916-A6AA-40A3-8D94-F39908029CB4Q35348258-6E936259-8AD4-42D7-8A27-E943EAB782AEQ35447413-52075EFB-DF6D-48BA-A90F-BB8593C54F98
P2860
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Role of pharmacokinetics in the outcome of infections.
@en
Role of pharmacokinetics in the outcome of infections.
@nl
type
label
Role of pharmacokinetics in the outcome of infections.
@en
Role of pharmacokinetics in the outcome of infections.
@nl
prefLabel
Role of pharmacokinetics in the outcome of infections.
@en
Role of pharmacokinetics in the outcome of infections.
@nl
P2860
P356
P1476
Role of pharmacokinetics in the outcome of infections.
@en
P2093
Drusano GL
P2860
P304
P356
10.1128/AAC.32.3.289
P407
P577
1988-03-01T00:00:00Z